Andere Sprachen FibroBiologics, Inc.

Aktien

A3EP67

US31573L1052

FBLG

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
11,99 ^USD	+4,44 %		+9,00 %	0,00 %

14.05.	FibroBiologics, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
25.04.	FibroBiologics, Inc. plant eine Zusammenarbeit mit Charles River Laboratories zur Herstellung von Sphäroiden auf Fibroblastenbasis	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

FibroBiologics Announces 2024 Annual Meeting of Stockholders	15.05.
FibroBiologics Files 2024 First Quarter Report	14.05.
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
FibroBiologics to Present at the BIO International Convention 2024	07.05.
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids	25.04.
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	25.04.
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office	11.04.
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA	04.04.
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA	04.04.
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus	28.03.
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	20.03.
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment	19.03.
FibroBiologics to Present at Advanced Wound Care Summit USA	13.03.
FibroBiologics Appoints Ruben A. Garcia as General Counsel	06.03.
FibroBiologics, Inc. Appoints Ruben A. Garcia as General Counsel	06.03.
FibroBiologics Files 2023 Form 10-K Annual Report	29.02.
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Top Premarket Gainers	28.02.
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	21.02.
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen FibroBiologics, Inc.

Aktien

A3EP67

US31573L1052

FBLG

Andere Sprachen

Filter